Trials / Withdrawn
WithdrawnNCT05628545
Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
Clinical Study on Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Guangdong GD Kongming Biotech LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Brief Summary: In this study, effects of γδ T cells on Advanced hepatocyte carcinoma The goal of this clinical trial is to learn about effects of allogeneic γδ T therapy in advanced hepatocyte carcinoma patients. The main question it aims to answer is:Will advanced hepatocyte carcinoma patients be benefit from allogeneic γδ T therapy? Participants will received GDKM-100injection (allo-γδ T Cells) Infusion every two weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GDKM-100 injection | Participants will received GDKM-100injection (allo-γδ T Cells) Infusion every two weeks. |
Timeline
- Start date
- 2021-11-01
- Primary completion
- 2023-02-28
- Completion
- 2024-10-31
- First posted
- 2022-11-28
- Last updated
- 2023-01-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05628545. Inclusion in this directory is not an endorsement.